ATAZANAVIR SULFATE | A091673 | TEVA PHARMACEUTICALS USA
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Lachman Consultant Services Inc FDA-2014-P-0980 · 4 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of a client requesting that the FDA determine whether REYATAZ (atazanavir sulfate) Capsules, 100 mg, approved under NDA 21-567, was voluntarily withdrawn from the market for safety or efficacy reasons rather than commercial reasons, in | 505(q) | 2014-07-11 | Denied | Lachman Consultant Services Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.56
per ea
Lowest NADAC/Unit
$1.09
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093552856ATAZANAVIR SULFATE 300 MG CAP | $2.56 | EA | Generic | — | 2026-06-17 |
| 00093552706ATAZANAVIR SULFATE 200 MG CAP | $1.09 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.